• Publications
  • Influence
Antiallergic effect of ZCR-2060: antihistaminic action.
TLDR
Results indicate that ZCR-2060 has a potent, selective and long acting histamine H1-receptor antagonistic action without causing any unwanted CNS side effect. Expand
Antiallergic effects of ZCR-2060: effect on allergic cutaneous reactions and rhinitis models in mice and rats.
TLDR
The results suggest that ZCR-2060 has antiallergic effects on allergic cutaneous reactions and experimental rhinitis, probably due to histamine H1-receptor blockage and the inhibition of histamine release. Expand
Effects of ZCR‐2060 on Allergic Airway Inflammation and Cell Activation in Guinea‐pigs
TLDR
Results indicate that ZCR‐2060 inhibits allergic airway inflammation, and PAF‐induced inflammatory cell activation in guinea‐pigs, and may prove useful for the treatment of allergicAirway inflammation or allergic disorders, especially inflammatory cell infiltration and activation. Expand
Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion.
TLDR
The results indicate that consecutive administration of nizatidine may cause only a transient increase of gastric acid secretion but no hypergastrinaemia after its withdrawal, and changes in basal gastric Acid secretion and serum gastrin level after withdrawal of cimetidine and ranitidine administered for 14 consecutive days are studied. Expand
Effect of ZCR-2060, an antiallergic agent, on antigen-induced immediate- and late-phase increases in airway resistance in sensitized guinea pigs.
TLDR
ZCR-2060 has a potent protective effect on immediate- and late-phase increases in Rrs and was stronger than that of ketotifen, terfenadine and cetirizine, and was almost the same as that of prednisolone. Expand
Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 3rd communication: inhibitory effects on histamine release from lung fragments, Schultz-Dale reaction
TLDR
Experimental asthma was clearly inhibited in a dose-dependent fashion by oral administration of WP-833, and antigen-mediated SD reaction of isolated tracheal muscle without showing antagonistic actions upon histamine- and leukotriene D4-induced contraction of normal trachea muscle. Expand
Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 2nd communication: inhibitory effects on histamine release from rat mast cells and lung fragments.
TLDR
WP-833 showed non-competitive inhibition of cyclic AMP-dependent phosphodiesterase derived from lung preparations and inhibited in a dose-dependent fashion immunoglobulin E (IgE)-mediated histamine release from mast cells. Expand
Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 1st communication: effects on type I to type IV allergic reactions in animal models.
TLDR
Findings demonstrating that WP-833 clearly inhibited type I allergic reaction, systemic Forssman shock in guinea pigs and reversed cutaneous anaphylaxis in rats (type II), passive Arthus reaction in rats, and contact dermatitis and tuberculin reaction in mice (type IV) were unaffected byWP-833 even in higher doses than in those capable of completely inhibiting type I allergy reaction. Expand
Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 4th communication: effects on histamine release from human leukocytes and from human and monkey lung
TLDR
WP-833 showed no inhibition of antigen, anti-immunoglobulin E (IgE)- and calcium ionophore A23187-induced histamine release from leukocytes of atopic patients allergic to house dust mite, and prolonged pretreatment of lung fragments with WP-833 resulted in a decay in inhibition of anaphylactic Histamine release. Expand
...
1
2
...